CClinicalTrials.gg
Sign In
CompletedNCT05261438Updated Mar 2, 2022

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

An observational study in Non-squamous NSCLC, sponsored by Hunan Province Tumor Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Hunan Province Tumor Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Study summary

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Read the detailed description

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

02

Conditions studied

  • Non-squamous NSCLC
03

In context

Carcinoma, Non-Small-Cell Lung

6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.

This study's enrollment of 70 is below the median of 161 across 949 observational studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Hunan Province Tumor Hospital is the lead sponsor of 72 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Advanced Metastatic Non-squamous Non-small Cell Lung Cancer

Inclusion criteria

18，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel

Exclusion criteria

Exclusion Criteria:

Patients with contraindication of chemotherapy Pregnant or breast feeding women

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
70 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. OS

    overall survival

    Time frame: September 2019- september 2021

  2. PFS

    progression-free survival

    Time frame: September 2019- september 2021

07

Study locations

1 site
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05261438
Lead sponsor
Hunan Province Tumor Hospital
Responsible party
Yongchang Zhang (HunanPTH, Hunan Province Tumor Hospital) — Principal investigator
First posted
Mar 2, 2022
Start date
Sep 1, 2019
Primary completion
May 1, 2021
Completion
Sep 15, 2021
Last update
Mar 2, 2022

Study contacts

Yongchang Zhang, MD
principal investigator · Hunan Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma, Non-Small-Cell Lung→

Other studies from this sponsor

Hunan Province Tumor Hospital

Start the discussion